



Treatment Data Recording (phase I)

Version 28-06-2023

Contents

Background	3
Aims of the Recommendation	4
ENTERING INTO FORCE	4
Defining Treatment and Types of Treatments.....	5
1. SURGERY	6
2. RADIOTHERAPY	8
3. SYSTEMIC THERAPY.....	10
4. STEM CELL TRANSPLANTATION	12
5. REASON FOR NO TREATMENT	12
References	13
Appendix 1: Working Group Members.....	14
Appendix 2: Anatomical Therapeutic Chemical (ATC) Codes, Generic and Trade Names	15

Contact: ENCR Secretariat
JRC-ENCR@ec.europa.eu

DRAFT

Background

In Europe, many population-based cancer registries are collecting, routinely or for some specific projects, data related to cancer stage and treatment. Routine collection of clinical data is possible for registries, for example by active registration method when registering a new cancer and/or by linking incident cases with external information sources, such as hospital discharge and outpatient records, health insurance reimbursement data or drug prescriptions¹. Despite the fact that the collection of cancer stage at diagnosis is well defined the principles of collecting data on treatment raise doubts and are not standardised at the European level.

This data allows the:

- Monitoring of treatment patterns;
- Assessment of the compliance with clinical guidelines;
- Evaluation of new treatments at population level

In order to use treatment data it is essential to ensure their comparability at a European level. This requires harmonisation of variables across European population-based cancer registries. The ability to analyse such data is of particular interest for every individual country/region as well as for the European Commission initiatives to reduce cancer mortality and improve patient outcomes. Cancer diagnosis, stage at diagnosis and treatment are some of the key pillars of the Commission Europe's Beating Cancer Plan, which aims to provide better integrated and comprehensive cancer care and to evaluate accessibility to quality care and medicines².

In this context, the European Network of Cancer Registries (ENCR) Steering Committee and the European Commission's Joint Research Centre (JRC) set up in June 2021 the Working Group on Treatment Data Harmonisation in order to recommend collection of treatment data and to reflect on guidelines for the harmonisation of treatment variables in European population-based cancer registries.

¹ Giusti (2023), De Angelis (2019), Siesling (2015), Coebergh (2012), Gatta (2010).

² European Commission (2021).

Aims of the Recommendation

The aim of the present document is to provide the first recommendations for treatment data collection and coding to the population-based cancer registries, in order to improve data harmonisation and comparability in Europe.

Specific objectives of the present document are:

- Formulate a clear recommendation for cancer registries to collect data on treatment
- Formulate a clear general definition of treatment, by type (e.g. surgery, radiotherapy and systemic therapies)

ENTERING INTO FORCE

The new ENCR Recommendations on Treatment Data Recording (phase one) is published on the website on ##-##-2023. These recommendations should be applied to all tumours with an incidence date as of 1-1-2024, but may also be applied to earlier dates.

DRAFT

Defining Treatment and Types of Treatments

For the purpose of the present recommendations, anticancer treatment is defined as **first course** procedures, given within a fixed time frame after diagnosis.

This definition excludes:

- diagnostic procedures,
- interventions that do not have (potential) effect on the tumour,
- second line (disease progression) and further courses of therapy (e.g. interventions for recurrence after disease free interval).

A *multi-tiered* system approach has been defined by the Working Group on Treatment Data Harmonisation for each type of treatment to meet the differences in resources engaged in data collection process between European CR's and their possibility to collect detailed data.

Tier 1 consists in the minimum required information, whereas *tier 2 (and above)* include more detailed information, to be used for instance for the evaluation of clinical guidelines.

The present recommendations introduce the first phase of this approach, and give guidance on tier 1 treatment data recording. This document will be followed in a second phase by guidelines on the collection of more detailed treatment information (*tier 2 and above*), for different cancer entities.

Following the latest *Call for Data protocol for European Population-Based cancer registries*³, organised by the JRC and the ENCR, treatment types (modalities) are divided between:

- **surgery,**
- **radiotherapy,**
- **systemic therapies** (chemotherapy, targeted therapy [including immunotherapy], hormone therapy, other - such as corticosteroids - or unspecified).

³ <https://encr.eu/call-for-data>.

1. SURGERY

Surgery is defined as a resection of the primary tumour. Following the latest *Call for Data protocol for European Population-Based Cancer Registries*, for some cancer sites additional procedures which leave the organ in situ, such as cryosurgery, laser coagulation, thermoablation and radiofrequency ablation (RFA) should be also part of this category, but these procedures should be identifiable as such.

A time frame of nine months from diagnosis should be considered.

Possible information sources:

- hospital discharge records are one of the main surgery data sources in Europe for cancer registries. Some of the most commonly used classification are, ICD-9-CM⁴, ICD-10-PCS⁵, ICHI⁶, OPCS-4⁷, OPS⁸, or modifications of these systems (e.g. the Swiss CHOP classification⁹),
- another frequently used source of surgery data are clinical records (including interdisciplinary tumour boards reports), which are currently *electronic health records* in many European Union member states¹⁰,
- outpatient records (which can be relevant, for instance, for skin cancers),
- pathology reports and
- insurance reimbursement claims/data.

The information (*tier 1*) to be collected for all cancer entities is described in **Table 1**.

⁴ International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), Volume 3.

⁵ International Classification of Diseases, Tenth Revision Procedure Coding System

⁶ International Classification of Health Interventions

(<https://www.who.int/standards/classifications/international-classification-of-health-interventions>)

⁷ OPCS Classification of Interventions and Procedures Fourth Revision. NHS England 2022.

⁸ German procedure classification (Operationen- und Prozedurenschlüssel - OPS), Federal Institute for Drugs and Medical Devices 2023.

⁹ Swiss classification of operations (CHOP), Swiss Federal Statistical Office 2020.

¹⁰ Milieu Ltd, Time.lex. Overview of the national laws on electronic health records in the EU member states and their interaction with the provision of cross-border eHealth services. Brussels, Consumers, health and food executive agency (Chafea), 2014.

Additional variables include information on the hospital of surgery. This could be important for the assessment of centralisation level and accessibility, and for monitoring the efficiency and effectiveness of the health system in cancer treatment.

Table 1. *Surgery (all cancer entities): variables description, format, missing/unknown values and coding schema.*

Variable description	Format	Missing/ unknown	Coding
Surgery	F	9	0→No 1→Yes, no specified 2→Yes, local surgery only 3→Yes, 'operative' surgery
Day of surgery	F	99	Range of allowed values: From 1 to 31
Month of surgery	F	99	Range of allowed values: From 1 to 12
Year of surgery	F	9999	≥ Year of incidence
Hospital of surgery	A	9	National coding system

F: Numeric variable A: Alphanumeric variable

2. RADIOTHERAPY

Radiotherapy is defined for the present purpose as the use of radiation in a radical approach of destroying and/or shrinking tumours. It can be given as the only treatment, used before surgery to shrink the tumour (neoadjuvant radiotherapy), given during (intra-operative radiotherapy) or after surgery (adjuvant radiotherapy) to reduce the risk of recurrence. In addition, radiotherapy can also be used along with systemic cancer treatment, concurrently or sequentially. Radiotherapy for oligometastatic disease at diagnosis (i.e. with a limited number of treatable metastases¹¹) should also be collected.

A time frame of twelve months from diagnosis should be considered.

Possible information sources

- Hospital discharge and, increasingly, outpatient records are important data sources in Europe for cancer registries. Some of the used classifications, like ICD-9-CM, have very limited information on type of radiotherapy.
- Another main source are specific radiotherapy information systems and datasets (e.g. the National Radiotherapy Dataset in England¹²)
- Information on radiotherapy could be derived from clinical records (including interdisciplinary tumour boards reports)
- Other sources of information are notifications of cancers and insurance reimbursement claims/data.
- Pathology reports could mention neo-adjuvant or intraoperative radiotherapy.

The information to be collected on radiotherapy is described in **Table 2**. If date of start and stop are available they should be collected, and if also date of surgery is available the setting (e.g. neoadjuvant) can be derived from this. As an alternative, information on the order should be registered.

Additional variables include information on the centre of radiotherapy. This could be important for monitoring, for instance, outcome in relation to centre characteristics.

¹¹ See for instance the definition of oligometastatic disease in colorectal cancer in the *ESMO consensus guidelines for the management of patients with metastatic colorectal cancer*.

¹² Radiotherapy Data Set (RTDS) User Guide. Public Health England 2021.

Table 2. Radiotherapy (all cancer entities): variables description, format, missing/unknown values and coding schema.

Variable description	Format	Missing/ unknown	Coding
Radiotherapy	F	9	0 → No 1 → Yes
Radiotherapy in relation to surgery	F	9	1 → Radiotherapy only 2 → Yes, neoadjuvant (pre-operative) radiotherapy 3 → Yes, intra-operative radiotherapy 4 → Yes, adjuvant (post-operative) radiotherapy
Radiotherapy in relation to systemic therapy	F	9	1 → Radiotherapy only 2 → Yes, concurrent with systemic therapy 3 → Yes, sequential use to systemic therapy
Day of radiotherapy start	F	99	Range of allowed values: From 1 to 31
Month of radiotherapy start	F	99	Range of allowed values: From 1 to 12
Year of radiotherapy start	F	9999	≥ Year of incidence
Day of radiotherapy stop	F	99	Range of allowed values: From 1 to 31
Month of radiotherapy stop	F	99	Range of allowed values: From 1 to 12
Year of radiotherapy stop	F	9999	≥ Year of incidence
Radiotherapy centre	A	9	National coding system

3. SYSTEMIC THERAPY

In line with the latest *Call for Data protocol for European population-based cancer registries*, systemic therapies are categorised as:

- chemotherapy,
- targeted therapy, including monoclonal antibodies,
- immunotherapy, excluding monoclonal antibodies,
- hormone therapy,
- other or unspecified systemic therapy.

Targeted therapy comprises all drugs that block the growth of cancer cells by inhibition of certain pathways in the cancer cell. Traditional chemotherapy also affects other cells in the body that divide quickly. The main categories of targeted therapy are small molecules (mostly tyrosine kinase inhibitors such as imatinib and many other *-nibs*) and monoclonal antibodies (such as rituximab and many other *-mabs*).

A time frame of twelve months from diagnosis should be considered.

Possible information sources

- Hospital discharge and, increasingly, outpatient records are important data sources in Europe for cancer registries. Some of the used classifications, like ICD-9-CM, can only report if therapy was received or not.
- One of the main sources are hospital drugs databases and pharmaceutical prescription databases.
- Information on systemic therapy could be derived from clinical records (including interdisciplinary tumour boards reports).
- Other sources of information are notifications and insurance reimbursement claims/data.
- Pathology reports could mention neoadjuvant systemic therapy.

The information to be collected on systemic therapy is described in **Table 3**. If date of start and stop are available they should be collected, and if also date of surgery is available the timing (e.g. neoadjuvant) can be derived from this.

Additional variables include information on the centre of delivery of systemic therapy. Even though more and more patients receive systemic therapy outside the care centre, this could

be important for monitoring, for instance, outcome in relation to centre characteristics. A list of systemic therapy codes by type, according to the Anatomical Therapeutic Chemical (ATC) Classification System, with generic and trade names is reported in **Annex 2**.

Table 3. Systemic therapy variables description, format, missing/unknown values and coding schema.

Variable description	Format	Missing/ unknown	Coding
Systemic therapy, first-line	F	9	0 → No 1 → Yes, without other specification 2 → Yes, neoadjuvant (pre-operative) 3 → Yes, adjuvant (post-operative) 4 → Yes, both neoadjuvant and adjuvant
Day of systemic therapy start	F	99	Range of allowed values: From 1 to 31
Month of systemic therapy start	F	99	Range of allowed values: From 1 to 12
Year of systemic therapy start	F	9999	≥ Year of incidence
Day of systemic therapy end	F	99	Range of allowed values: From 1 to 31
Month of systemic therapy end	F	99	Range of allowed values: From 1 to 12
Year of systemic therapy end	F	9999	≥ Year of incidence
Systemic therapy type	A	9	Condensed systemic therapy type 1 → Chemotherapy 2 → Targeted therapy (including monoclonal antibodies) 3 → Immunotherapy (excl. monoclonal antibodies) 4 → Hormone therapy 5 → Other or unspecified
Systemic therapy centre	A	9	National coding system

4. STEM CELL TRANSPLANTATION

Table 4. *Stem cell variable description.*

Variable description	Format	Missing/ unknown	Coding
Stem cell transplantation (SCT)	F	9	0 → No 1 → Yes
Day of SCT	F	99	Range of allowed values: From 1 to 31
Month of SCT	F	99	Range of allowed values: From 1 to 12
Year of SCT	F	9999	≥ Year of incidence

5. REASON FOR NO TREATMENT

Table 5. *Reason for no treatment variable description.*

Variable description	Format	Missing/ unknown	Coding
<i>Reason for no anticancer treatment</i>	F	9	1 → Watchful waiting 2 → Active surveillance 3 → Refusal 4 → Symptomatic treatment only 5 → Unspecified 6 → Patient's death

Watchful waiting is a type of expectant management, mostly used in prostate cancer. It is an option for patients who are not suitable for (or unwilling to have) treatment. It can be used in with a slow progression, or when treatment risks might be greater than possible benefits. Active surveillance is another expectant management strategy of close monitoring, mostly used in prostate cancer and urethral cancer. The monitoring normally requires regular biopsies and tests on a regular schedule¹³.

¹³ See for instance *Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up* and the NCI Dictionary of Cancer Terms.

References

- Giusti F, Martos C, Trama A, Bettio M, Sanvisens A, Audisio R et al. *Cancer treatment data available in European cancer registries: where are we and where are we going?* *Front Oncol.* 2023 Feb 8;13:1109978. doi: [10.3389/fonc.2023.1109978](https://doi.org/10.3389/fonc.2023.1109978).
- De Angelis R, Rossi S, Tagliabue G, Tittarelli A, Barigelletti G, Milena Sant et al. Innovative Partnership for Action Against Cancer (iPAAC), Task 7.1 *Advancing registries data through integration with administrative data sources. Mapping data sources available for linkage with registry data.* Version 2.0 (2019).
- Siesling S, Louwman WJ, Kwast A, van den Hurk C, O'Callaghan M, Rosso S et al. *Uses of cancer registries for public health and clinical research in Europe: Results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010–2012* *Eur J Cancer.* 2015 Jun;51(9):1039-49. doi: [10.1016/j.ejca.2014.07.016](https://doi.org/10.1016/j.ejca.2014.07.016).
- Coebergh JW, Eurocourse Executive Board & Steering Board. Eurocourse brochure: *Cancer Registries in Europe – Serving cancer surveillance and research 1988–2012–2020.* Eindhoven: Eindhoven Cancer Registry/Comprehensive Cancer Center South; 2012.
- Gatta G, Zigon G, Aareleid T, Ardanaz E, Bielska-Lasota M, Galceran J et al. Patterns of care for European colorectal cancer patients diagnosed 1996-1998: a EUROCORE high resolution study. *Acta Oncol.* 2010 Aug;49(6):776-83. doi: [10.3109/02841861003782009](https://doi.org/10.3109/02841861003782009).
- European Commission (2021). COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. [Europe's Beating Cancer Plan](#).
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D. *ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.* *Ann Oncol.* 2016 Aug;27(8):1386-422. doi: [10.1093/annonc/mdw235](https://doi.org/10.1093/annonc/mdw235).

Appendix 1: Working Group Members

Francesco Giusti (European Commission/Belgian Cancer Registry), Riccardo Audisio (Sahlgrenska University Hospital, Göteborg, Sweden), Yolande Lievens (Ghent University Hospital and Ghent University, Ghent, Belgium), Carmen Martos (European Commission/FISABIO, Valencia, Spain), Claudia Allemani (London School of Hygiene and Tropical Medicine), Volker Arndt (German Cancer Research Centre - DKFZ), Manola Bettio (European Commission), Roberta De Angelis (Istituto Superiore di Sanità, Rome, Italy), Henna Degerlund (Finnish Cancer Registry), Silvia Francisci (National Health Institute, Rome, Italy), Gemma Gatta (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Anna Gavin (Northern Ireland Cancer Registry), Tom Børge Johannesen (Cancer Registry of Norway), Margit Mägi (Estonian Cancer Registry), Rafael Marcos-Gragera (Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain), Eva Morris (Nuffield Department of Population Health, Big Data Institute, University of Oxford, UK), Regina Nanieva (National Institute for Cancer Epidemiology and Registration - NICER, Switzerland), Raquel Negrão Carvalho (European Commission), Laura Pareja Fernandez (Department of Health of Catalonia, Hospitalet del Llobregat, Barcelona, Spain), Francesco Pignatti (European Medicines Agency), Josepa Ribes Puig (Department of Health of Catalonia, Hospitalet del Llobregat, Barcelona, Spain), Silvia Rossi (Istituto Superiore di Sanità, Rome, Italy), Arantza Sanvisens (Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain), Annalisa Trama (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Maciej Trojanowski (Greater Poland Cancer Registry), Ulrich Wagner (National Institute for Cancer Epidemiology and Registration – NICER, Switzerland), Paul Walsh (National Cancer Registry Ireland), Vesna Zadnik (Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Slovenia), Otto Visser (Netherlands Comprehensive Cancer Organisation - IKNL), Liesbet Van Eycken (Belgian Cancer Registry)

Appendix 2: Anatomical Therapeutic Chemical (ATC) Codes, Generic and Trade Names

Chemotherapy

ATC code	Generic name	Trade name
L01AA01	Cyclophosphamide	ENDOXAN
		CYCLOPHOSPHAMIDE
		GENOXAL
		LEDOXINA
		SENDOXAN
		DEMACYLAN
L01AA02	Chlorambucil	LEUKERAN
		CHLORAMINOPHÈNE
		CHLORAMBUCIL
L01AA03	Melphalan	ALKERAN
		MELFALAN
		MELPHALAN
L01AA05	Chlormethine	LEDAGA
L01AA06	Ifosfamide	HOLOXAN
		IFOSFAMIDE
		TRONOXAL
L01AA09	Bendamustine	LEVACT
		BENDAMUSTINE
		AUBEDIX
		BENMAK
		RIBOMUSTIN
		BENDAMYL
		BENDISTIN
		BENTALYA
		LEDUFAN
		LYNETORIL
		MUSTINAL
		NIVOBRAL
		RHOMUSTIN
		RIBOVACT
TABINAZ		

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01AB01	Busulfan	MYLERAN
		BUSULFEX
		BUSILVEX
L01AB02	Treosulfan	TRECONDI
		TREOSULFAN
		OVASTAT
L01AC01	Thiotepa	TEPADINA
		THIOPLEX
L01AD01	Carmustine	BICNU
		CARMUBRIS
		GLIADEL
		CARMUSTINE OBVIUS
L01AD02	Lomustine	BELUSTINE
		CECENU
		LOMUSTINE
L01AX03	Temozolomide	TEMODAL
		TEMODAR
		TEMCAD
		TEMOMEDAC
L01AX04	Dacarbazine	DTIC
L01BA01	Methotrexate	JYLAMVO
		OTREXUP
		RASUVO
		METHOTREXATE
		METOJECT
		EMTHEXATE
		TREXAN
		NORDIMET
L01BA03	Raltitrexed	TOMUDEX
L01BA04	Pemetrexed	ALIMTA
		ARMISARTE
		CIAMBRA

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01BA04	Pemetrexed (<i>cont.</i>)	PEMFEXY
L01BB02	Mercaptopurine	PURI-NETHOL
		XALUPRINE
		MERCAPTOPURINE
		MEDIPURIN
L01BB03	Tioguanine	LANVIS
		THIOGUANIN
		THIOSIX
L01BB04	Cladribine	LEUSTATIN
		MAVENCLAD
		LITAK 10
L01BB05	Fludarabine	FLUDARA
		FLUDARABINE
		FLUMEN
L01BB05	Fludarabine	SINDARABIN
		BENDARABIN
		FLUDALYM
L01BB06	Clofarabine	EVOLTRA
		IVOZALL
L01BB07	Nelarabine	ATRIANCE
L01BC01	Cytarabine	ALEXAN
		CYTARABINE
		CYTOSAR
		DEPOCYTE
L01BC02	Fluorouracil	FLUOROURACIL
		FLUOROURACIL 5
		5-FU
		EFUDIX
		FLUORAXAN
		FLURABLASTIN
		FLURACEDYL
		RIBOFLUOR
L01BC05	Gemcitabine	GEMCITABINE
		GEMBIN

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01BC05	Gemcitabine (<i>cont.</i>)	GEMZAR
L01BC06	Capecitabine	CAPECITABINE
		XELODA
		COLOXET
		ECANSYA
L01BC07	Azacitidine	VIDAZA
L01BC08	Decitabine	DACOGEN
L01BC09	Floxuridine	FUDR
L01BC52	Fluorouracil, combinations	FLUOROURACIL
L01BC53	Tegafur combinations	UFT
		FTORAFUR
		TEYSUNO
		UTEFOS
L01BC59	Trifluridine, combinations	LONSURF
		THIOL
		VIROPHTA
L01CA01	Vinblastine	VINBLASTIN
		VELBAN
		VELBE
		CYTOBLASTIN
L01CA02	Vincristine	VINCRISTIN
		ONCOVIN
		VINCRISIN
		VINCRISUL
		VINCASAR PFS
		FARMISTIN
		CYTOCRISTIN
		CELLCRISTIN
L01CA03	Vindesine	ELDISINE
		GESIDINE
		ENISON
L01CA04	Vinorelbine	NAVELBINE
		VINORELBIN

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01CA04	Vinorelbine (<i>cont.</i>)	NAVIN
		NAVIREN
L01CA05	Vinflunine	JAVLOR
L01CB01	Etoposide	ETOPOSIDE
		ETOPOPHOS
		TOPOSAR
		VEPESID
		LASTET
		CELLTOP
		EPOSIN
		ETOMEDAC
		ETOSID
		EXITOP
L01CB02	Teniposide	VUMON
L01CD01	Paclitaxel	PACLITAXEL
		TAXOL
		PACLITAXIN
		ABRAXANE
		SINDAXEL
		ANZATAX
		ARITAXEL
		BENDATAX
		BIOTAXEL
		BREVITAX
		EBETAXEL
		EUCOL
		GENEXOL
		LETPAR
		PACLIXEL
		PACOVARY
		PATAXEL
		PAXENE
PAXITAL		
TAXOMEDAC		

Chemotherapy (cont.)

ATC code	Generic name	Trade name
L01CD02	Docetaxel	TAXOTERE
		DOCETAXEL
		BENDADOCEL
		CAMITOTIC
		CETADOCURE
		DEMOTAXEL
		DOCEXEL
		DOTAXEL
		DOXEL
		DOXEN
		EDOXEL
		FINAXEL
		QVIDADOTAX
		RIBODOCEL
		SYMTAXEL
		TAXCEUS
		TAXEGIS
		TAXESPIRA
		TAXOVINA
		TEDOCAD
TOLNEXA		
DOCETAX		
L01CD04	Cabazitaxel	J EVTANA
L01CX01	Trabectedin	YONDELIS
L01DA01	Dactinomycin	COSMEGEN
L01DB01	Doxorubicin	DOXORUBICIN
		CAELYX
		ADRIBLASTIN
		DEBDOX
		MYOCET
		XORUCIN
		ADRIMEDAC
		AXIDOXO
		DOXIPROL

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01DB01	Doxorubicin (<i>cont.</i>)	DOXOTIL
		FARMIBLASTINA
		RASTOCIN
		RUBIDOX
		SINDROXCIN
L01DB02	Daunorubicin	DAUNOXOME
		CERUBIDIN
		DAUNOBLASTINA
		DAUNORUBICIN
L01DB03	Epirubicin	FARMORUBICIN
		EPIRUBICIN
		EPILEM
		EPISINDAN
		AXIRUBICIN-E
		BENDAEPI
		CENEPIR
		CIAZIL
		EPI TEVA
		EPIBRA
		EPIMEDAC
		EPIRUB
		MEGARUBICIN
		RIBOEPI
		RUBENS
L01DB06	Idarubicin	ZAVEDOS
		IDARUBICIN
		IDAMEN
L01DB07	Mitoxantrone	MITOXANTRON
		ONCOTRONE
		NOVANTRONE
		STRIMAX
		EBEXANTRON
		ELSEP
		RALENOVA

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01DB07	Mitoxantrone (<i>cont.</i>)	GENEFADRONE
		REFADOR
		XANTROSIN
L01DB11	Pixantrone	PIXUVRI
		PIXUVIR
L01DC01	Bleomycin	BLEOCIN
		BLEOMYCIN
		BLEO-KYOWA
		BLEOLEM
		BLEOMEDAC
		BLEOCELL
L01DC03	Mitomycin	MITOMYCIN C
		AMETYCINE
		MITEM
		MITO-EXTRA
		MITO-MEDAC
		MITOSTAT
		MUTAMYCIN
		UROCIN
L01XA01	Cisplatin	CISPLATIN
		SINPLATIN
		PLATINOL
		PLATIDIAM
		PLATINEX
		ESOPLATIN
		PLATAMINE
		PLATOSIN
		CISPLATYL
		CITOPLATINO
		NEOPLATIN
		PLACIS
		PLATISTIL
PLATISTINE		
L01XA02	Carboplatin	CARBOPLATIN

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01XA02	Carboplatin (<i>cont.</i>)	PARAPLATIN
		AXICARB
		BOPACATIN
		CARBATACIN
		CARBOMEDAC
		CARBOPLAN
		CARBOPLASIN
		CARBOSIN
		CARMEN
		CYCLOPLATIN
		HAEMATO-CARB
		MEGAPLATIN
		EMORZYM
		PLATINWAS
		L01XA03
OXALIPLATIN		
AXIPLATIN		
BENDAPLATIN		
ELATOFEN		
GENEPLATIN		
GESSEDIL		
LINOXA		
LINOXAL		
LIVELLIN		
MEDOXA		
OXALIMED		
OXALIPROL		
OXALISIN		
OXALIZOR		
OXAPLAMYL		
OXAVIATIN		
PLATOX		
RECTOXAL		
RIBOXATIN		

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01XA03	Oxaliplatin (<i>cont.</i>)	SINOXAL
		VELMINOX
		XOPLAN
L01XB01	Procarbazine	NATULAN
		PROCARBAZINE
L01XX01	Amsacrine	AMSIDYL
		AMEKRIN
		AMSACRINE
		AMSALYO
L01XX02	Asparaginase	AMSIDINE
		ASPARAGINASE
		ERWINASE
		KIDROLASE
L01XX03	Altretamine	SPECTRILA
		HEXALEN
L01XX05	Hydroxycarbamide	HEXASTAT
		HYDREA
		HYDROXYCARBAMID
		SIKLOS
		HYDREASYN
		HYDROXYUREA
		LITALIR
ONCO-CARBIDE		
L01XX08	Pentostatin	NIPENT
L01XX11	Estramustine	ESTRACYT
		ESTRAMUSTIN
		MULTOSIN
L01XX14	Tretinoin	VESANOID
		TRETINOIN
L01XX17 (L01CE01 from 01/01/2021)	Topotecan	HYCAMTIN
		TOPOTECAN
		POTACTASOL
		LUTECAN
		TOPOCAN

Chemotherapy (cont.)

ATC code	Generic name	Trade name
	Topotecan (cont.)	TOPOVIN
L01XX19 (L01CE02 from 01/01/2021)	Irinotecan	IRINOTECAN
		CAMPTO
		ONIVYDE
		IRINOTESIN
		CAMPTERIL
		IRITEC
		VIARITEC
		ARINOTEC
		IRICAM
		IRICAN
		IRINOCAN
		IRINOCOL
		IRINOKABI
		IRINOLIQUID
		IRINOMEDAC
		IRINOSYN
		IRINTO
		MIZANTRONE
		NEOTECAN
		NEVOTECAM
NOXECAN		
RIBOIRINO		
SANTACIL		
TEKAMEN		
VINTECAN		
XAVETTA		
L01XX23	Mitotane	LYSODREN
L01XX24	Pegaspargase	ONCASPAR
L01XX25	Bexarotene	TARGRETIN
L01XX27	Arsenic trioxide	TRISENOX
		ARSENIC TRIOXIDE
L01XX32	Bortezomib	VELCADE
		BORTEZOMIB

Chemotherapy (*cont.*)

ATC code	Generic name	Trade name
L01XX32	Bortezomib (<i>cont.</i>)	BORTEADE
		BORTECLARMIA
		BORTEGA
		SANGREL
		VORTEMYEL
		ZEGOMIB
L01XX41	Eribulin	HALAVEN
L01XX42	Panobinostat	FARYDAK

DRAFT

Hormonal therapy

ATC code	Generic name	Trade name
G03AC05	Megestrol acetate	MEGOXI
		MEGYRINA
		O'TENTIKA
		BOREA
		CACHEXAN
		GESTROL
		MAYGACE
		MEGALIA
		MEGAPLEX
		MEGASTRIL
		MEGEFREN
		MEGESIN
		MEGESTAT
		MEGESTIL
		MEGESTROL
G03DA02	Medroxyprogesterone acetate	PROVERA
		FARLUTAL
		SAYANA
		CLIMANOR
		CYKRINA
		DEPO-CLINOVIR
		DEPOCON
		DEPO-PRODASONE
		PROGEVERA
		ELASHINE
		MPA
		PRODAFEM
		SAYANAJECT

Hormonal therapy (cont.)

ATC code	Generic name	Trade name
G03HA01	Cyproterone acetate	ANDROCUR
		IMVEL
		ANDRO-DIANE
		ANDROTERONE
		CYPROPLEX
		CYPROSTAT
		CYPROTERON
		CYSAXAL
		ERAPYL
H03AA01	Levothyroxine sodium	ELTROXIN
		EUTHYROX
		EUTIROX
		ALTHYXIN
		BERLTHYROX
		DEXNON
		EFEROX
		LETROX
		LEVAXIN
		LEVIROX
		LÉVOTHYROX
		LEVOXYL
		L-THYROXINE
		THYRAX
H03AA02	Liothyronine sodium	CYNOMEL
		CYTOMEL
		THYBON
H03AA03	Combinations of levothyroxine and liothyronine	EUTHYRAL
		NOVOTHYRAL
L02AA02	Polyestradiol phosphate	ESTRADURIN
L02AB03	Gestonorone caproate	DEPOSTAT
L02AE01	Buserelin	SUPREFACT
		SUPRECUR
		METRELEF
		PROFACT

Hormonal therapy (cont.)

ATC code	Generic name	Trade name
L02AE02	Leuprorelin	ELIGARD
		LUCRIN DEPOT
		LEUPRORELIN
		LEPTOPROL
		LEUPROSTIN
		LUPRON
		LUTRATE DEPOT
		DARONDA
		DEPO-ELIGARD
		ENANTON DEPOT
		ENANTONE
		GINECRIN DEPOT
		LECTRUM
		LERIN
		LEUPROL
		LEUPRONE HEXAL
		LUTRATE
		POLITRATE
		PROCREN DEPOT
		PROCRIN
PROSTAP		
PROSTAPLANT		
SIXANTONE		
TRENANTONE		
L02AE03	Goserelin	ZOLADEX
		ALGONAD
		GOLEXIN
		RESELIGO
		XANDERLA
L02AE04	Triptorelin	DECAPEPTYL
		DIPHERELINE
		GONAPEPTYL
		ARVEKAP
		TRIPTOFEM

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02AE04	Triptorelin (<i>cont.</i>)	MOAPAR
		SALVACYL
L02AE05	Histrelin	VANTAS
L02BA01	Tamoxifen	NOLVADEX
		TAMOXIFEN
		TAMIFEN
		SOLTAMOX
		NOVOFEN
		ADIFEN
		KESSAR
		NOMAFEN
		TADEX
		TAMEC
		TAMIZAM-20
		TAMOPLEX
		TAMOX - 1 A PHARMA
		TAMOXENE
		ZITAZONIUM
ZYMOPLEX		
L02BA02	Toremifene	FARESTON
L02BA03	Fulvestrant	FASLODEX
		FALVAX
		FULVESTRANT
L02BB01	Flutamide	FLUTASIN
		FLUTAMIDE
		APO-FLUTAM
		ELBAT
		EULEXIN
		FLUMID
		FLUPROSIN
		FLUTAN
		FLUTASTAD
		GRISETIN
PROFAMID		

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BB01	Flutamide (<i>cont.</i>)	PROSNEO
		PROSTACUR
		PROSTANDRIL
		RICALIDE
		FLUCINOM
L02BB03	Bicalutamide	BICALUTAMIDE
		CASODEX
		ANDROBLOC
		ANDROCAL
		APEX
		BELANTIS
		BICACEL
		BICACTA
		BICADEX
		BICALAN
		BICALGEN
		BICALODEX
		BICALOX
		BICALUPLEX
		BICALUSTAD
		BICALUT
		BICALUTAGEN
		BICALUTANORM
		BICALUTIN
		BICAMED
		BICAMIDE
		BICAPROCAN
		BICAPROL
		BICAPROX
		BICA-Q
		BICARBEX
BICASTAD		
BICATIN		
BICLUTIDE		

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BB03	Bicalutamide (<i>cont.</i>)	BICUSAN
		BIKALARD
		BIKALEN
		BIKALIS
		BILUMID
		BILUMIDE
		BILURON
		BINABIC
		BIOBICA
		BIXALAN
		BJORGEINA
		CALUMID
		CALUTIN
		CAPRO
		ENCALOR
		KALUFAR
		LANBICA
		LUTAMID
		LUTRAK
		OMIDEX
		ORMANDYL
		PRAXIS
		PROBIC
		PROBICON
PROCADEX		
PROCURE		
SAFEDEX		
SAVEPROST		
TOSADEX		
VERODEX		
WIBICAL		
YONISTIB		
ZARMOL		
L02BB04	Enzalutamide	XTANDI

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BB05	Apalutamide	ERLEADA
L02BB06	Darolutamide	NUBEQA
L02BG01	Aminoglutethimide	ORIMETEN
		MAMOMIT
		AMINOGLUTETHIMID
		ROGLUTEN
L02BG03	Anastrozole	ARIMIDEX
		ANASTROZOL
		AGERDEX
		ALOXEX
		ALTRAVESA
		AMENUR
		ANABLOCK
		ANABREST
		ANALIS
		ANAPREX
		ANAROMAT
		ANASTAR
		ANASTELB
		ANASTRALAN
		ANASTRAZE
		ANASTRIS
		ANASTRO-CELL
		ANASTROGEN
		ANASTROHEXAL
		ANASTROLAN
		ANASTROMIN
		ANASTROZEX
		ANAYA
		ANAZOL
		ANKARMA
		ANSYN
		APO-NASTROL
		AREMED

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BG03	Anastrozole (<i>cont.</i>)	ARILLA
		ARMOTRAZ
		ASTRALIS
		ASTRAZOL
		ATROCELA
		ATROZOL
		AXASTROL
		AZONET
		BARSTRA
		DELTASOLDE
		EGISTROZOL
		EPSISOLDE
		ERISTROL
		EXTROPLEX
		GAMMASOLDE
		KYARESTA
		LONDER
		MAMMOZOLE
		MAMOSTROL
		MIVISIA
		NASTRIN
		OZOLAN
		RAOLOZ
		RENAZOLE
		RIMIDAL
		STRAKIR
		STRAZOLAN
TRASOLETTE		
ZELOTRIN		
ZOLITRAT		
ZOLKIR		
ZOLZYN		
ZYNZOL		

Hormonal therapy (cont.)

ATC code	Generic name	Trade name
L02BG04	Letrozole	FEMARA
		LETROZOL
		ALETRO
		AROMED
		AROMEK
		AVOMIT
		CALANTHA
		CLARZOLE
		DRACENAX
		ELOZORA
		ETRUZIL
		FAMOS
		FEMAPLEX
		FEMAR
		FEMAZAC
		FEMOZOL
		FEMTOZONE
		FLORAZOLE
		GALDAR
		GOSURAN
		LAMETTA
		LEONCON
		LERANA
		LETMYLAN
		LETRAFEM
		LETRALAN
		LETRASAN
		LETRAXON
		LETRILAN
		LETROBLOCK
LETROFAM		
LETROFAR		
LETROFEM		
LETROFEMIN		

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BG04	Letrozole (<i>cont.</i>)	LETROGER
		LETROHEXAL
		LETROLAN
		LETROMAL
		LETROMAN
		LETROMEDAC
		LETROMYL
		LETROPEN
		LETROSTAR
		LETROVENA
		LETROZIN
		LETROZOLUM
		LETROZOMAX
		LEVETIRACETAM
		LEZRA
		LIKARDA
		LOOSYN
		LORTANDA
		LOSTAR
		LOTESTROL
		LOXIFAN
		LOXOPREL
		MIONIC
		PICOZETTE
		PICOZONE
		RATROZ
		RELIGAN
		SADERON
		SILETRIS
		STEFAPLEX
		SYMLETROL
		TROZARA
TROZEL		
VIOBREST		

Hormonal therapy (*cont.*)

ATC code	Generic name	Trade name
L02BG04	Letrozole (<i>cont.</i>)	ZEQUIPRA
L02BG06	Exemestane	AROMASIN
		EXEMESTAN
		ALMESTEN
		ALVOSTAN
		AROMAPLEX
		AROMASIL
		AROMESTAN
		AROSTANIL
		ASTEXANA
		AXELTA
		COTAMOX
		ESCEPRAN
		ETADRON
		EXEDRAL
		EXEGEN
		EXEMESIN
		EXEMIN
		EXEREGIO
		EXESTAN
		GEPEX
GLANDEX		
INPLAVIA		
MEMELIN		
NATERAN		
NODUTAX		
PERAMIT		
PIEXTANE		
SYMEX		
XANEPRA		
L02BX01	Abarelix	PLENAXIS
L02BX02	Degarelix	FIRMAGON
L02BX03	Abiraterone acetate	ZYTIGA

Targeted therapy

ATC code	Generic name	Trade name
L01XC02	Rituximab	MABTHERA
		BLITZIMA
		RITEMVIA
		RITUZENA
		RIXANTHON
		RIXATHON
		RIXIMYO
		TRUXIMA
		TUXELLA
L01XC03	Trastuzumab	HERCEPTIN
		HERZUMA
		KADCYLA
		KANJINTI
		ONTRUZANT
		TRAZIMERA
L01XC04 (L04AA34 from 01/01/2015)	Alemtuzumab	LEMTRADA
		MABCAMPATH
L01XC05	Gemtuzumab ozogamicin	MYLOTARG
L01XC06	Cetuximab	ERBITUX
L01XC07	Bevacizumab	AVASTIN
		MVASI
L01XC08	Panitumumab	VECTIBIX
L01XC09	Catumaxomab	REMOVAB
L01XC10	Ofatumumab	ARZERRA
L01XC11	Ipilimumab	YERVOY
L01XC12	Brentuximab vedotin	ADCETRIS
L01XC13	Pertuzumab	PERJETA
L01XC14	Trastuzumab emtansine	KADCYLA
L01XC15	Obinutuzumab	GAZYVARO
		GAZYVA
L01XC16	Dinutuximab beta	UNITUXIN
		DINUTUXIMAB BETA
		QARZIBA

Targeted therapy (*cont.*)

ATC code	Generic name	Trade name
L01XC17	Nivolumab	OPDIVO
		NIVOLUMAB
L01XC18	Pembrolizumab	KEYTRUDA
L01XC19	Blinatumomab	BLINCYTO
L01XC21	Ramucirumab	CYRAMZA
L01XC22	Necitumumab	PORTRAZZA
L01XC23	Elotuzumab	EMPLICITI
L01XC24	Daratumumab	DARZALEX
		DARATUMUMAB
L01XC25	Mogamulizumab	POTELIGEO
L01XC26	Inotuzumab ozogamicin	BESPONSA
L01XC27	Olaratumab	LARTRUVO
L01XC28	Durvalumab	IMFINZI
L01XC29	Bermekimab	XILONIX
L01XC31	Avelumab	BAVENCIO
		AVELUMAB
L01XC32	Atezolizumab	TECENTRIQ
L01XC33	Cemiplimab	LIBTAYO
L01XE01 (L01EA01 from 01/01/2021)	Imatinib	GLIVEC
		IMATINIB
		ANZOVIP
		ASTREA
		DEVATINIB
		EGITINID
		GLIPOX
		IMAKREBIN
		IMAREM
		IMATENIL
		IMAVEC
		ITIVAS
		LATIB
LETINIB		
LEUTIPOL		

Targeted therapy (*cont.*)

ATC code	Generic name	Trade name
L01XE01 (L01EA01 from 01/01/2021)	Imatinib (<i>cont.</i>)	LEUZEK
		MARIMAB
		MEAPAX
		MEAXIN
		NEOPAX
		NIBIX
		TELUX
		TIBALDIX
		HRONILEUCEM
		IMAGEROLAN
		IMANIVEC
		IMATEK
		MYLAUKIM
		NEOXELL
VIANIB		
L01XE02 (L01EB01 from 01/01/2021)	Gefitinib	IRESSA
		GEFITINIB
		GEFINOR
L01XE03 (L01EB02 from 01/01/2021)	Erlotinib	TARCEVA
		ERLOTINIB
		VARLOTA
		MITROXELEN
L01XE04 (L01EX01 from 01/01/2021)	Sunitinib	SUTENT
		SUNITINIB
L01XE05 (L01EX02 from 01/01/2021)	Sorafenib	NEXAVAR
L01XE06 (L01EA02 from 01/01/2021)	Dasatinib	SPRYCEL
		DASATINIB
L01XE07 (L01EH01 from 01/01/2021)	Lapatinib	TYVERB
L01XE08 (L01EA03 from 01/01/2021)	Nilotinib	TASIGNA
L01XE09 (L01EG01 from 01/01/2021)	Temsirolimus	TORISEL
L01XE10 (L01EG02 from 01/01/2021)	Everolimus	CERTICAN
		AFINITOR
		VOTUBIA
		ADEROLIO

Targeted therapy (*cont.*)

ATC code	Generic name	Trade name
L01XE10 (L01EG02 from 01/01/2021)	Everolimus (<i>cont.</i>)	EVEROLIMUS
		LINEVERO
L01XE11 (L01EX03 from 01/01/2021)	Pazopanib	VOTRIENT
L01XE12 (L01EX04 from 01/01/2021)	Vandetanib	CAPRELSA
L01XE13 (L01EB03 from 01/01/2021)	Afatinib	GIOTRIF
L01XE14 (L01EA04 from 01/01/2021)	Bosutinib	BOSULIF
L01XE15 (L01EC01 from 01/01/2021)	Vemurafenib	ZELBORAF
L01XE16 (L01ED01 from 01/01/2021)	Crizotinib	XALKORI
L01XE17 (L01EK01 from 01/01/2021)	Axitinib	INLYTA
L01XE18 (L01EJ01 from 01/01/2021)	Ruxolitinib	JAKAVI
L01XE21 (L01EX05 from 01/01/2021)	Regorafenib	STIVARGA
L01XE23 (L01EC02 from 01/01/2021)	Dabrafenib	TAFINLAR
L01XE24 (L01EA05 from 01/01/2021)	Ponatinib	ICLUSIG
L01XE25 (L01EE01 from 01/01/2021)	Trametinib	MEKINIST
L01XE26 (L01EX07 from 01/01/2021)	Cabozantinib	COMETRIQ
		CABOMETYX
		CABLIVI
L01XE27 (L01EL01 from 01/01/2021)	Ibrutinib	IMBRUVICA
L01XE28 (L01ED02 from 01/01/2021)	Ceritinib	ZYKADIA
L01XE29 (L01EX08 from 01/01/2021)	Lenvatinib	KISPLYX
		LENVIMA
L01XE31 (L01EX09 from 01/01/2021)	Nintedanib	OFEV
		VARGATEF
L01XE33 (L01EF01 from 01/01/2021)	Palbociclib	IBRANCE
L01XE34 (L01EK03 from 01/01/2021)	Tivozanib	FOTIVDA
L01XE35 (L01EB04 from 01/01/2021)	Osimertinib	TAGRISSO
L01XE36 (L01ED03 from 01/01/2021)	Alectinib	ALECENSA
L01XE38 (L01EE02 from 01/01/2021)	Cobimetinib	COTELLIC
L01XE39 (L01EX10 from 01/01/2021)	Midostaurin	RYDAPT
		MIDOSTAURINE
L01XE41 (L01EE03 from 01/01/2021)	Binimetinib	MEKTOVI
L01XE42 (L01EF02 from 01/01/2021)	Ribociclib	KISQALI
L01XE43 (L01ED04 from 01/01/2021)	Brigatinib	ALUNBRIG
L01XE44 (L01ED05 from 01/01/2021)	Lorlatinib	LORVIQUA

Targeted therapy (*cont.*)

ATC code	Generic name	Trade name
L01XE45 (L01EH02 from 01/01/2021)	Neratinib	NERLYNX
L01XE46 (L01EC03 from 01/01/2021)	Encorafenib	BRAFTOVI
L01XE47 (L01EB07 from 01/01/2021)	Dacomitinib	VIZIMPRO
L01XE50 (L01EF03 from 01/01/2021)	Abemaciclib	VERZENIOS
L01XE51 (L01EL02 from 01/01/2021)	Acalabrutinib	CALQUENCE
L01XE52 (L01EX11 from 01/01/2021)	Quizartinib	VANFLYTA
L01XE53 (L01EX12 from 01/01/2021)	Larotrectinib	VITRAKVI
L01XE54 (L01EX13 from 01/01/2021)	Gilteritinib	XOSPATA
L01XE56 (L01EX14 from 01/01/2021)	Entrectinib	ROZLYTREK
L01XX43 (L01XJ01 from 01/01/2021)	Vismodegib	ERIVEDGE
L01XX44	Aflibercept	ZALTRAP
L01XX45 (L01XG02 from 01/01/2021)	Carfilzomib	KYPROLIS
L01XX46 (L01XK01 from 01/01/2021)	Olaparib	LYNPARZA
L01XX47 (L01EM01 from 01/01/2021)	Idelalisib	ZYDELIG
L01XX48 (L01XJ02 from 01/01/2021)	Sonidegib	ODOMZO
L01XX50 (L01XG03 from 01/01/2021)	Ixazomib	NINLARO
L01XX52	Venetoclax	VENCLYXTO
L01XX54 (L01XK02 from 01/01/2021)	Niraparib	ZEJULA
L01XX55 (L01XK03 from 01/01/2021)	Rucaparib	RUBRACA
L01XX60 (L01XK04 from 01/01/2021)	Talazoparib	TALZENNA
L01XX61 (L01EM02 from 01/01/2021)	Copanlisib	ALIQOPA
L01XX63 (L01XJ03 from 01/01/2021)	Glasdegib	DAURISMO
L01XX65 (L01EM03 from 01/01/2021)	Alpelisib	PIQRAY
L04AX02	Thalidomide	THALIDOMIDE
L04AX04	Lenalidomide	REVLIMID
		LENALIDOMIDE
L04AX06	Pomalidomide	IMNOVID

Immunotherapy

ATC code	Generic name	Trade name
L01XX51	Talimogene laherparepvec	IMLYGIC
L03AA02	Filgrastim	NEUPOGEN
		TEVAGRASTIM
		FILGRASTIM
		ACCOFIL
		NIVESTIM
		RATIOGRASTIM
		GRASTOFIL
		ZARZIO
		BIOGRASTIM
		GRANULOKINE
		GRASALVA
L03AA10	Lenograstim	GRANOCYTE
		MYELOSTIM
L03AA13	Pegfilgrastim	NEULASTA
		NEULASTIM
		NEUPOPEG
		RISTEMPA
L03AA14	Lipegfilgrastim	LONQUEX
		LONGUEX
L03AB01	Interferon alfa natural	ALFAFERONE
		EGIFERON
		MULTIFERON
L03AB04	Interferon alfa-2a	ROFERON-A
L03AB05	Interferon alfa-2b	REALDIRON
		INTRON A
		INTRONA
		REFERGEN
		VIRAFERON
L03AC01	Aldesleukin	PROLEUKIN
L03AX03	BCG vaccine	BCG-MEDAC
		IMMUCYST
		ONCOTICE
		ONKO

Other therapies

ATC code	Generic name	Trade name
A04AA01	Ondansetron	ZOFTRAN
		ONDANSETRON
		EMETRON
		NOVETRON
		ONDA
		ONDANSAN
		ONDASAN
		ONDATRAN
		ONDAVELL
		SETOFILM
		SETRONON
		VAMETAL
		ZONDARON
		ZOTRON
		ATOSSA
		AVESSARON
		CRUZAFEN
		DENTRON
		MIZOF
		ODASEN
		ONDAGEN
		ONDAMETON
		ONDANTOR
		ONDEMET
		ONSETROGEN
		OSETRON
		SETRODAN
		TRONDAMET
		VEFRON
		ZETRON
ZOFSETRON		
ZOPHRALEN		
ZOPHREN		
ZYTRON		

Other therapies (*cont.*)

ATC code	Generic name	Trade name
A04AA02	Granisetron	KYTRIL
		GRANISETRON
		SANCUSO
		GRANEGIS
		RASETRON
		AXIGRAN
		EMEGAR
		EMETRIL
		GRAFTOR
		GRANIGEN
		GRANORED
		GRATEVA
		RIBOSETRON
		VIATRINIL
A04AA03	Tropisetron	NAVOBAN
		NOVABAN
		TROPISETRON
A04AA04	Dolasetron	ANZEMET
A04AA05	Palonosetron	ALOXI
		PALONOSETRON
		FERANT
		INJOSETRON
B03XA01	Erythropoietin	NEO RECORMON
		EPREX
B03XA02	Darbepoetinalfa	ARANESP
B03XA03	Pegzerepoetinalfa	MIRCERA
B03XA06	Luspatercept	REBLOZYL
H02AB02	Dexamethasone	DEXAMETHASONE
		OZURDEX
		DECADRON
		MAXIDEX
H02AB04	Methylprednisolone	MEDROL

Other therapies (*cont.*)

ATC code	Generic name	Trade name
H02AB04	Methylprednisolone (<i>cont.</i>)	METHYLPREDNISOLON
		ADVANTAN
H02AB06	Prednisolone	PREDNISOLONE
		DECORTIN
H02AB07	Prednisone	DELTACORTISONE
		DELTACORTONE
		DELTACORTENE
		DELTISONE
		DEHYDROCORTISON
M05BA02	Clodronic acid	SINDRONAT
		BONEFOS
		OSTAC
		CLASTEON
		CLASTOBAN
		CLIMACLOD
		CLODEOSTEN
		CLODRON
		CLODY
		DIFOSFONAL
		LODRONAT
		LORON
		LYTOS
		MOTICLOD
		NEOGRAND
		NIKLOD
M05BA03	Pamidronic acid	OSTEONORM
		OSTEOSTAB
		PAMITOR
		PAMIDRONAT
		AREDIA
M05BA06	Ibandronic acid	PAMIFOS
		PAMIPRO
		BONVIVA
		BONDRONAT

Other therapies (*cont.*)

ATC code	Generic name	Trade name
M05BA06	Ibandronic acid (<i>cont.</i>)	IASIBON
		IBANDRONATE
		IVADRON
		KEFORT
		OSSICA
		PHACEBONATE
M05BA08	Zoledronic acid	ACLASTA
		ZOMETA
		ZOLEDRONIC ACID
		ZERLINDA

DRAFT